Alterome Therapeutics, Inc. develops alteration-specific small molecule therapies using a structure-guided machine learning platform to target validated oncogenic drivers in cancer patients with limited treatment options. The company aims to provide precise therapeutic solutions that improve patient outcomes and inspire hope in the fight against cancer.
Funding
$231.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GSFounders
Product
Problem
Many cancer patients with validated oncogenic drivers have limited treatment options, highlighting the need for more precise and effective therapies. Existing treatments often lack the specificity required to target these drivers, leading to suboptimal outcomes.
Solution
Alterome Therapeutics develops alteration-specific small molecule therapies designed to precisely target validated oncogenic drivers in cancer. The company utilizes a structure-guided machine learning platform, referred to as "Kraken", to accelerate the discovery and development of these therapies. This computational chemistry platform enables the design of precision medicines that address a broad spectrum of validated oncogenic targets. By focusing on alteration-specific treatments, Alterome aims to improve patient outcomes and provide more effective therapeutic solutions.
Target Audience
The primary target audience includes cancer patients with specific, validated oncogenic drivers and the oncologists treating them.
Features
- Structure-guided drug discovery approach for alteration-specific therapies
- "Kraken" in-house computational chemistry platform
- Focus on validated oncogenic drivers with limited treatment options
- Development of precision small molecule therapies